The FDA has approved Mirati Therapeutics’ Krazati in combination with cetuximab, for the treatment of adult patients with KRAS G12C-mutated locally advanced or metastatic colorectal cancer, or CRC, as determined by an FDA-approved test, who have received prior treatment with fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapy, according to an amended label posted to the agency’s website. On January 23, Bristol Myers Squibb (BMY) announced that it had successfully completed its acquisition of Mirati Therapeutics.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BMY:
- Bristol Myers says FDA grants accelerated approval of Augtyro
- I-Mab announces clinical trial collaboration with Bristol Myers
- Bristol Myers: Opdivo+Yervoy improved OS vs Lenvatinib or Sorafenib in HCC
- UroGen Pharma announces David Lin as chief commercial officer
- Bristol Myers announces results from Phase 3 KRYSTAL-12 study